Alyssa Levin
Director of Finance/CFO en NKARTA, INC. .
Fortuna: 605 360 $ al 31/03/2024
Perfil
Alyssa Levin is currently the Chief Financial & Business Officer at Nkarta, Inc. She previously worked as the Chief Financial Officer at ViaCyte, Inc. She received an undergraduate degree from the University of British Columbia and a graduate degree from Edwards School of Business.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NKARTA, INC.
0.08% | 04/01/2024 | 56 000 ( 0.08% ) | 605 360 $ | 31/03/2024 |
Cargos activos de Alyssa Levin
| Empresas | Cargo | Inicio |
|---|---|---|
| NKARTA, INC. | Director of Finance/CFO | 05/07/2023 |
Antiguos cargos conocidos de Alyssa Levin.
| Empresas | Cargo | Fin |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director of Finance/CFO | 05/07/2023 |
Formación de Alyssa Levin.
| University of British Columbia | Undergraduate Degree |
| Edwards School of Business | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NKARTA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Alyssa Levin
